Population-based study of association of metformin use and survival of gastric adenocarcinoma

Metformin use may improve the prognosis in gastric adenocarcinoma, but the existing literature is limited and contradictory. A Swedish population-based cohort study of diabetes patients who were diagnosed with gastric adenocarcinoma found that compared with non-users, metformin users had a decreased risk of disease-specific mortality (HR 0.79; 95% CI 0.67-0.93) and all-cause mortality (HR 0.78; 95% CI 0.68-0.90). The associations were stronger among women, patients with tumor stage III or IV, and patients with the least comorbidity.